



HAL
open science

CDDO and ATRA Instigate Differentiation of IMR32 Human Neuroblastoma Cells

Namrata Chaudhari, Priti Talwar, Christian Lefebvre d'Hellencourt,
Palaniyandi Ravanan

► **To cite this version:**

Namrata Chaudhari, Priti Talwar, Christian Lefebvre d'Hellencourt, Palaniyandi Ravanan. CDDO and ATRA Instigate Differentiation of IMR32 Human Neuroblastoma Cells. *Frontiers in Molecular Neuroscience*, 2017, 10, 10.3389/fnmol.2017.00310 . hal-02300890

HAL Id: hal-02300890

<https://hal.univ-reunion.fr/hal-02300890>

Submitted on 30 Sep 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License



CDDO and ATRA Instigate Differentiation of IMR32 Human Neuroblastoma Cells

Namrata Chaudhari¹, Priti Talwar¹, Christian Lefebvre D'hellencourt² and Palaniyandi Ravanan^{1*}

¹ Apoptosis and Cell Survival Research Lab, Department of Biosciences, School of Biosciences and Technology, VIT University, Vellore, India, ² Université de La Réunion, Institut National de la Santé et de la Recherche Médicale, UMR Diabète Athérombose Thérapies Réunion Océan Indien, Saint-Denis de La Réunion, France

Neuroblastoma is the most common solid extra cranial tumor in infants. Improving the clinical outcome of children with aggressive tumors undergoing one of the multiple treatment options has been a major concern. Differentiating neuroblastoma cells holds promise in inducing tumor growth arrest and treating minimal residual disease. In this study, we investigated the effect of partial PPAR γ agonist 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid (CDDO) on human neuroblastoma IMR32 cells. Our results demonstrate that treatment with low concentration of CDDO and particularly in combination with all trans retinoic acid (ATRA) induced neurite outgrowth, increased the percentage of more than two neurites bearing cells, and decreased viability in IMR32 cells. These morphological changes were associated with an increase in expression of bona fide differentiation markers like β 3-tubulin and Neuron Specific Enolase (NSE). The differentiation was accompanied by a decrease in the expression of *MYCN* whose amplification is known to contribute to the pathogenesis of neuroblastoma. *MYCN* is known to negatively regulate NMYC downstream-regulated gene 1 (NDRG1) in neuroblastomas. *MYCN* down-regulation induced by CDDO correlated with increased expression of NDRG1. CDDO decreased Anaplastic Lymphoma Kinase (*ALK*) mRNA expression without affecting its protein level, while ATRA significantly down-regulated *ALK*. Antagonism of PPAR γ receptor by T0070907 meddled with differentiation inducing effects of CDDO as observed by stunted neurite growth, increased viability and decreased expression of differentiation markers. Our findings indicate that IMR32 differentiation induced by CDDO in combination with ATRA enhances, differentiation followed by cell death via cAMP-response-element binding protein (CREB) independent and PPAR γ dependent signaling mechanisms.

Keywords: synthetic triterpenoid, differentiation, peroxisome proliferator activated receptor gamma

OPEN ACCESS

Edited by:

Ildikó Rácz,
University Hospital Bonn, Germany

Reviewed by:

Laura Maria Frago,
Universidad Autonoma de Madrid,
Spain

Shasta Sabo,
Central Michigan University,
United States

*Correspondence:

Palaniyandi Ravanan
ravanan.p@vit.ac.in

Received: 16 April 2017

Accepted: 14 September 2017

Published: 26 September 2017

Citation:

Chaudhari N, Talwar P, Lefebvre D'hellencourt C and Ravanan P (2017) CDDO and ATRA Instigate Differentiation of IMR32 Human Neuroblastoma Cells. *Front. Mol. Neurosci.* 10:310. doi: 10.3389/fnmol.2017.00310

INTRODUCTION

Cell fate determination and differentiation are processes that are crucial in developmental biology, which assigns cells their functional roles and gives them unique identity. Cell differentiation is an essential process. It is a result of differential gene expression, epigenetic modifications, ceased proliferation, and morphological changes converting the precursor cells to specialized ones

committed to a specific lineage (Slack, 2012). The differentiation process is paused in certain cancer cells and it is possible that the process could be resumed using relevant differentiation inducing agents, assisting the cancer cells to acquire a terminally differentiated state (Jimenez and Yunis, 1987). Therapeutic application of differentiation therapy successfully made Acute Promyelocytic Leukemia (APL) a curable disease with the use of all trans retinoic acid (ATRA) to differentiate immature leukemic promyelocytes into mature granulocytes (Warrell et al., 1991). In 1971, Barry Pierce and Carol Wallace had put forward a proof of concept that certain malignant cells can differentiate into benign cells. Evidence from their research on squamous cell carcinoma supports the idea that a progeny of malignant stem cells can differentiate into post-mitotic benign squamous cells incapable of forming a tumor (Pierce and Wallace, 1971).

In the first decade of twentieth century, three pioneers: James Homer Wright, William Pepper, and Robert Grieve Hutchison, contributed in delineating the pathology of neuroblastoma in pediatric patients with distinctive clinical presentations (Rothenberg et al., 2009). Neuroblastoma is an extracranial cancer derived from embryonic precursor cells that form the primitive neural crest. These cells are destined to produce multipotent progenitor cells that respond to the ligands and transcription factors, and initiate a regulated signaling cascade to give rise to the peripheral nervous system, the enteric nervous system, pigment cells, Schwann cells, adrenal medullary cells, and cells of the craniofacial skeleton. This differentiation process is forestalled in neuroblastoma making it a heterogeneous disease with variable clinical behavior and outcome. Several studies have reported the underlying genetic and biological causes for neuroblastoma like gene amplification, activating gene mutations, inactivating gene mutations, ploidy, segmental chromosomal abnormalities, single nucleotide polymorphisms, and epigenetic alterations (Schleiermacher et al., 2014). A phenomenon observed in certain younger children with neuroblastoma is a spontaneous complete regression with or without mild chemotherapy (Brodeur and Bagatell, 2014).

Differentiation therapy could be used in combinatorial treatment by inducing regression and steering the cells to complete the differentiation process. Pharmacological modulation of the differentiation signaling pathways in diseases is currently gaining considerable attention. Consequently, it is vital to find novel differentiation triggering agents that can be used in treatment regimens of diseases having a glitch in the differentiation pathways (Kawamata et al., 2006; Andrew et al., 2012). Drugs that are capable of inducing differentiation to stop tumor growth at their earliest stages could be a superior choice either as an alternative or in addition to the existing cornerstone cancer therapies like radiation, chemotherapy, immunotherapy, and angiogenesis inhibition therapy (Allan and Travis, 2005; El-Kenawi and El-Remessy, 2013; Zhou, 2014).

Triterpenoids are a large family of structures synthesized in plants through the cyclization of squalene. Naturally occurring triterpenoids like oleanolic acid (OA) and ursolic acid (UA) are known to have relatively weak anti-inflammatory and anti-carcinogenic activities. In order to increase these activities, new synthetic derivatives have been created (Honda et al.,

1999, 2000). 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid (CDDO), identified as a partial PPAR γ agonist, is an inducer of apoptosis in myeloid leukemia cells, osteosarcoma cells, breast cancer cells, and colon cancer cells (Honda et al., 2000; Ito et al., 2001; Lapillonne et al., 2003; Ikeda et al., 2004; Zhang et al., 2004; Chintharlapalli et al., 2005). CDDO is also found to induce differentiation in human osteosarcoma cells and acute myeloid leukemia cells (AML-HL60), and enhances ATRA induced differentiation in NB4 and MR2 AML cells (Ito et al., 2001; Koschmieder et al., 2007; Tabe et al., 2007). Having knowledge of the versatile behavior of CDDO, we set forth a question “Could CDDO induce differentiation of neuroblastoma as well?” After treating the neuroblastoma cells with CDDO, we expected alterations in the following attributes: morphological changes, up-regulation of markers for differentiation, decrease in MYCN levels and finally activation of essential signaling pathways. It was interesting to find that CDDO as a single agent and in combination with ATRA induced differentiation of MYCN amplified IMR32 cells which to our knowledge is a first report demonstrating the ability of CDDO to induce neuroblastoma differentiation.

MATERIALS AND METHODS

Reagents and Cell Cultures

IMR32, a human neuroblastoma cell line was purchased from NCCS (Pune) and was maintained at 37°C in 5% humidified CO₂ atmosphere in Dulbecco's Modified Eagle Medium (DMEM, HiMedia). Media was supplemented with 10% fetal bovine serum (FBS, HiMedia), 1X antibiotic-antimycotic (HiMedia) and 1X glutamax (Gibco). CDDO and PPAR γ antagonist (T0070907) were purchased from Cayman. ATRA was purchased from Sigma Aldrich. Stocks were prepared in DMSO.

Cell Differentiation and Neurite Staining

For inducing differentiation, IMR32 cells were seeded in a 6-well plate at a density of 50,000 cells per well and treated with CDDO and ATRA alone and in combination for 5 days and the differentiation inducers were replenished on day 3 by changing the media. Cells were pre-incubated with T0070907 for 2 h prior to addition of CDDO. To observe the cell morphology and neurites, cells were washed with DPBS, prefixed for 2 min in media containing 3.7% formaldehyde and further fixed with DPBS containing 3.7% formaldehyde at -20°C. Permeabilization was done using absolute methanol at -20°C and finally cells were stained with methylene blue solution (0.2% methylene blue in methanol). Cells were imaged on EVOS FLoid Imaging Station (Thermo Fisher Scientific) equipped with a monochrome CCD camera. Neurites were traced using ImageJ software with neuron growth plug-in and represented as average total neurite length (μ m). For neurite length analysis, detectable neurites were measured from different focuses and cells without neurites were excluded from analyses. The total number and number of cells bearing more than two neurites were counted in 10 random focuses from independent experiments

and reported as a percentage. Control cells received the vehicle alone.

Cell Viability

Cell viability was estimated by measuring cellular ATP levels using CellTiter Glo luminescent assay (Promega) (Hannah et al., 2001). The assay uses luciferase reaction to measure ATP, which is proportional to the emitted luminescence signal. Briefly, 2,000 cells per well were seeded in 96-well plate (white) and treated as mentioned above. On day 5 the CellTiter Glo reagent was added to wells (50 μ l), mixed and luminescence was measured using a luminometer (Berthold).

The absolute number of viable cells was counted using trypan blue exclusion method. Briefly, 20,000 cells per well were seeded in 24-well plate and treated with differentiation inducers. At different experimental time points, both adhered and suspended cells were collected and stained with 0.4% trypan blue solution. Cells were counted manually using hemocytometer.

RNA Extraction, Reverse Transcriptase PCR (RT-PCR), and Quantitative Real-Time PCR (qPCR)

After inducing differentiation, cells were harvested at different time points. Total RNA from (both treated and control wells) the cultured cells were isolated using RNAiso Plus (Takara). RNA quality and quantity were assessed by Nanodrop UV-VIS spectrophotometer (Thermo Fisher Scientific). Two micrograms of total RNA from each sample was reverse transcribed to cDNA using Prime Script RT reagent kit (Takara). Using SYBR Premix Ex Taq (Tli RNase H Plus, Takara), RT-qPCR was performed on Applied Biosystems Step one plus PCR machine. The RNA 18S gene was amplified as an internal standard reference gene (invariant control). Fold changes in the target gene expression were normalized to 18S ribosomal RNA gene expression using comparative CT method ($2^{-\Delta\Delta CT}$ method) (Schmittgen and Livak, 2008).

Immunofluorescence

For immunofluorescence, 50,000 cells were seeded on gelatin coated coverslips in complete media and on the next day were treated with differentiation inducers. On day 5, cells were washed with DPBS, prefixed for 2 min in media containing 3.7% formaldehyde and further fixed with DPBS containing 3.7% formaldehyde at -20°C . Permeabilization was done using absolute methanol at -20°C . Primary antibodies employed for immunocytochemistry are anti- β 3-Tubulin (5568, Cell Signaling Technology, Danvers, MA, USA) and anti-Neuron Specific Enolase (NSE) (A3118; ABclonal Technology, USA). Alexa Fluor[®] 594 Conjugate goat anti rabbit (8889S, Cell Signaling Technology) was used as secondary antibody. Every step was followed according to manufacturer's instructions. The cells were counterstained with DAPI (HiMedia) in phosphate buffered saline for 5 min and the coverslips were mounted using fluoroshield (Sigma Aldrich, St Louis, MO, USA). Fluorescent images were acquired on EVOS FLoid Imaging Station using 20X fluorite objective and LED light cubes containing hard coated filters (blue and red), (Thermo Fisher Scientific).

Imaging parameters like brightness and contrast were kept constant throughout the experimental conditions for particular protein expression. No image modifications were done post imaging.

Western Blot Analysis

Media was aspirated and cells were washed with DPBS and lysates were obtained using RIPA buffer (20 mM Tris pH 7.5, 150 mM NaCl, 1 mM Na₂EDTA, 1 mM EGTA, 1% NP-40, 1% Sodium deoxycholate) supplemented with 1 mM PMSE, Protease inhibitor cocktail (Sigma Aldrich) and Phosphatase inhibitor cocktail (PhosSTOP, Roche). Cell lysates were passed several times through insulin syringe and incubated on ice for 30 min. Total protein was estimated by Lowry's method (Lowry et al., 1951). The extracted proteins were diluted and mixed with SDS-PAGE gel loading buffer to achieve a final concentration of 50 μ g/20 μ l (23 μ l aliquots were made for each protein and stored). The first gel run was performed with actin to confirm equal loading. Further to check protein expression, each time a gel was run with 20 μ l (50 μ g) loading volume. Stripping and re-probing were never performed. However, in a case of significant difference in the molecular weight of two proteins the membrane was cut horizontally. An equal amount of extracted total protein (50 μ g) was resolved in 10–12% SDS-PAGE and transferred onto polyvinylidene difluoride difluoride (PVDF) membranes (Fluoro Trans W, Pall Corporation). Blots were blocked with 5% skim milk in Tris buffered saline-Tween 20 (TBST) for 1 h and immunoblotted with specific rabbit anti human antibodies: PPAR γ Antibody (2443S) (Cell Signaling Technology); NDRG1 antibody (NBP1-32074) and ALK Antibody (NBP1-00710) (Novus Biologicals); ERK1/2 antibody (A0229), phospho ERK1/2 antibody (AP0472), CREB1 antibody (AP0019), and phospho CREB1 (AP0019) (ABclonal Technology, USA) for 3 h at room temperature. The membrane was then incubated for 1 h with anti-rabbit HRP conjugated secondary antibody (7074, Cell Signaling Technology). Immunocomplexes were visualized using enhanced chemiluminescence (ECL) chemistry (Mruk and Cheng, 2011) and developed on film (Fuji). Equal loading and transfer were validated by probing the membranes with beta actin antibody (8457S, Cell Signaling Technology).

Statistical Analysis

Statistical tests were performed using Graph Pad Prism6 software. Methylene blue staining and immunocytochemistry has been performed several times and reported as a representative image. All other experiments have been done twice and data is represented as an average of two independent experiments performed in triplicates except for trypan blue viability assay that was performed twice in duplicates. One-way ANOVA followed by Tukey's test was applied to compare more than two groups. Two-way ANOVA followed by Tukey's *post-hoc* test was applied to compare multiple groups (two parameters). Figure legends include mean \pm SEM and p values for the statistical analysis performed.

RESULTS

CDDO Alone and in Combination with ATRA Induces Neurite Outgrowth and Decreases Viability in IMR32 Cells

To test our hypothesis that synthetic triterpenoid CDDO could induce neuroblastoma differentiation; we initially performed a dose response experiment by treating IMR32 cells with various concentrations of CDDO (0.2, 0.5, 0.7, 1, 1.5, and 2 μ M) and observed for neurite outgrowth. We observed neurite outgrowth in treated cells at 0.5 and 0.7 μ M of CDDO whereas slightly higher concentrations of (1–2 μ M) induced cell death without displaying neuritogenesis in IMR32 cells. Similarly, a dose response experiment was performed with various concentrations of a known differentiation inducer, i.e., ATRA (5, 7.5, 10, and 15 μ M) and it revealed that ATRA 10 and 15 μ M induced neurite outgrowth. Subsequently, IMR32 cells were treated with 0.7 μ M CDDO individually, and also in combination with 10 μ M ATRA for 5 days to check the combinatorial effect. For comparison, we limited the ATRA treatment period to 5 days. CDDO treatment as a single agent exhibited delayed morphological changes. However, in combination with ATRA, initial sprouting of neurite was observed as early as day 3 and eventually, a branched neurite network between cells became apparent on day 5 for both the treatment conditions. A comparatively high rate of differentiation was observed in the cells that received the CDDO and ATRA treatment in combination compared to the cells that were treated only with CDDO. Vehicle control cells failed to exhibit aforementioned morphological features and continued to proliferate. At first, methylene blue staining was performed to determine the differentiation features (Figure 1A).

Neurite lengths were then semi-automatically traced on methylene blue stained images using ImageJ software (National Institute of Mental Health, Bethesda, Maryland, USA) with neuron growth plug-in (Universidad Nacionalg Autónoma de México, UNAM) (Fanti et al., 2008; Schneider et al., 2012). Data is represented as average total neurite length. Consistent with the morphological appearance, the cells treated with combination displayed maximum average total neurite length (Figure 1B, Supplementary Figure 1). CDDO treated cells exhibited a slight but significant concentration dependent increase in neurite length with the higher concentration of 1 μ M reducing cell viability and neurite outgrowth. A moderate yet significant increase in neurite length was noticed after treatment with CDDO in combination with ATRA, at various combinations of concentrations (Supplementary Figure 2A). The combination treatment also displayed a higher percentage of cells bearing more than two neurites when compared to individual treatments and control cells (Figure 1C).

Treatment with CDDO in both cases had a significant effect on cell viability with respect to untreated cells. CDDO alone and in combination with ATRA significantly reduced cell viability after 5 days of treatment, a phenomenon common to cells undergoing differentiation (Figures 1D,E). Further rounds of treatment up to 10 days with CDDO alone and in combination with ATRA reduced the viability, whereas ATRA treatment exhibited increased proliferation (Supplementary Figure 3).

CDDO at slightly higher concentrations (12 μ M) induced neurite outgrowth in Neuro2a, mouse neuroblastoma cells (Supplementary Figure 4). However, CDDO failed to induce neurite outgrowth in SHSY5Y, another human neuroblastoma cell line (Supplementary Figure 5).

Additionally, we performed experiments with serum free media, and media containing low percentage serum (0.5%) to check the effect of serum mitogens on IMR32 differentiation. In the absence of serum mitogens, control cells, CDDO, and ATRA treated cells lost the viability in 48 h. In case of medium containing 0.5% serum, CDDO treated cells struggled to produce neurites and maximum cells morphologically appeared dead after 5 days. ATRA induced certain neurite formation in low serum conditions but not as effective as in 10% serum containing media. In addition, reduced proliferation and unhealthy morphology were observed in treated as well as non-treated conditions in low and no serum conditions (Supplementary Figures 6, 7). Altogether, these results suggest that after 5 days of treatment, combination of CDDO with ATRA significantly decreased the cell viability with enhanced induction of neurite outgrowth in IMR32 cells.

CDDO Alone and in Combination with ATRA Up-Regulates Differentiation Markers

To validate the association of neuronal morphology with the expression of neuron specific markers, we first studied the expression of distinct neuronal markers like β 3-tubulin (encoded by *TUBB3*) and NSE (encoded by *ENO2*) by RT-qPCR. Although not exclusive, the expression of β 3-tubulin, a neuron associated tubulin isotype and NSE, a neuronal glycolytic isoenzyme is considered to be regulated during neuronal differentiation (Draberova et al., 1998; Jung et al., 2013). In agreement with the observed significant morphological differentiation; the gene expression of NSE was concurrently elevated under the treatment conditions with CDDO. Interestingly, β 3-tubulin mRNA expression decreased on day 3 and was maintained on day 5. In contrast, ATRA did not regulate NSE gene expression up to day 5 and decreased β 3-tubulin mRNA expression at both time points (Figures 2A,B).

Additionally, immunofluorescence was performed using β 3-tubulin and NSE antibodies following the treatment (Figures 2C,D, Supplementary Figures 8, 9). Immunofluorescence results indicated their increased expression in differentiated cells. Also, along with the experimental conditions negative antibody control (antibody diluent buffer) was included to ensure the fluorescence obtained is due to the primary antibody (Supplementary Figure 10). The β 3-tubulin expression was majorly extra nuclear in the neurites of cells treated with CDDO and/or ATRA. Pale cytoplasmic immunolabelling was observed in control cells. In the case of NSE, faint nuclear, and significant dispersed staining was observed in the neurites of the cells treated with CDDO, ATRA, and in combination compared to control cells. Altogether, these findings bring to light the potential of CDDO to stimulate differentiation in IMR32 cells in combination with ATRA,




FIGURE 1 | Continued

CDDO induces differentiation, enhances ATRA induced differentiation and decreases viability in IMR32 cells. **(A)** Cells were viewed under phase contrast microscope to study the morphological features of methylene blue stained IMR32 cells following treatment with CDDO 0.7 μ M and ATRA 10 μ M alone and in combination for 5 days. ATRA 10 μ M was used as positive control. The images were captured on a microscope equipped with a monochrome camera. **(B)** Stained images in triplicates per treatment condition were opened in ImageJ software and were analyzed using Neuron growth plug-in. Neurites were semi-automatically traced and lengths were expressed as mean neurite lengths. Error bars represent mean \pm SEM calculated using one-way ANOVA and Tukey's multiple comparison test. **(C)** The number of cells in treated and non-treated conditions with more than two neurites were counted from random focuses and represented as a percentage. Error bars represent mean \pm SEM calculated using one-way ANOVA and Tukey's multiple comparison test. **(D)** Cell viability of IMR32 cells was analyzed using CellTiter-Glo luminescent cell viability assay. Cells were treated with indicated concentrations for 5 days. Error bars represent mean \pm SEM calculated using one-way ANOVA and Tukey's multiple comparison test. **(E)** Cell viability of IMR32 cells was alternatively studied using trypan blue dye. Viable cells were counted manually using hemocytometer on day 2, 3, 4, and 5. Two independent experiments were performed in duplicates. Numbers on the y axis represent the total number of viable cells. Error bars represent mean \pm SEM calculated using two-way ANOVA and Tukey's multiple comparison test. “.” denotes significance with respect to control cells (DMSO treated), “@” denotes significance with respect to CDDO 0.7 μ M, and “!/#” denotes significance with respect to ATRA 10 μ M. DMSO (D); CDDO (C); CDDO + ATRA (CR); ATRA (R); four indicators: $p < 0.0001$; three indicators: $p \leq 0.001$; two indicators: $p \leq 0.01$; one indicator: $p \leq 0.05$.

as evidenced by an increase in mRNA and protein levels of neuroblastoma differentiation markers.

CDDO and ATRA Alter Expression of Genes Involved in Neuroblastoma Progression

A v-Myc related cellular sequence distinct from classical c-Myc oncogene was identified as N-Myc from the homogeneously staining regions (HSR) in IMR32 cells. MYCN was observed to be amplified by 50-folds in IMR32 cells relative to normal placental DNA (Kohl et al., 1983; Schwab et al., 1983). IMR32 cells are therefore MYCN amplified, and to assess the effects of CDDO on IMR32 cell differentiation pertaining to certain key genes regulated in neuroblastoma, RT-qPCR and western blotting was performed. We observed a radical decrease in MYCN levels in CDDO treated cells compared to ATRA treated and vehicle control cells. ATRA treatment had no effect on MYCN expression (**Figure 3A**). To verify and associate the MYCN expression pattern, MYCN downstream-regulated gene 1 (NDRG1) expression was studied. NDRG1 is repressed in cell lines with MYCN amplification and this down-regulation is known to be associated with MYCN effects in neuroblastomas (Li and Kretzner, 2003). The observed decrease in MYCN mRNA levels was accompanied by up-regulation of NDRG1 mRNA and its protein levels in CDDO treated cells and these results were consistent with IMR32 differentiation. NDRG1 was considerably less expressed in ATRA treated cells, possibly due to high MYCN mRNA levels (**Figures 3B,E**).

Human Anaplastic Lymphoma Kinase (ALK) is a tyrosine kinase receptor and a MYCN targeted oncogene. ALK can be mutated or amplified in neuroblastomas and contributes to the neuroblastomas progression. Also, ALK inhibition has been shown to decrease the biological effects of MYCN amplified cells/tumor growth in xenograft models (Hasan et al., 2013). A gain of function in ALK was observed in high-ALK expressing cells, having either a wild type or mutated receptor (Passoni et al., 2009). IMR32 cells express a wild type ALK receptor with no mutations nevertheless, co-amplification of MYCN and exon 3 and 4 of ALK as a fused single amplicon, has been reported to occur in these cells (Fransson et al., 2015). A considerable reduction in ALK mRNA level was observed in CDDO treated cells; whereas ATRA did not regulate ALK mRNA level. However, its protein expression was completely inhibited

in ATRA treated cells with no change in CDDO treated cells (**Figures 3C,E**). Because CDDO is a partial PPAR γ agonist, we studied if CDDO regulates *PPARG* levels. *PPARG* was found to be regulated by ATRA but not by CDDO. The mRNA levels were mirrored at protein levels as well (**Figures 3D,E**). These results indicate that CDDO and ATRA together had a distinctive contribution in tailoring the expression profile at both transcriptional and translational levels, reprogramming the cells to complete differentiation by decreasing their oncogenic properties.

PPAR γ Antagonist Inhibits CDDO Induced Differentiation in IMR32 Cells

Based on these findings, we decided to investigate the response of IMR32 cells to selective PPAR γ antagonist T0070907, knowing that CDDO is a partial agonist of PPAR γ (Honda et al., 2000). The exposure of 5 μ M T0070907 did not display cytotoxicity. The cells were exposed exclusively to T0070907 for 2 h and subsequently cultured for 5 days in presence of differentiation inducers; with the antagonist and inducers being replenished on day 3. The effects of CDDO were considerably inhibited by the antagonist, suggesting that the cellular responses were mediated at least in part by active PPAR γ receptor signaling. Antagonism of PPAR γ receptor by T0070907 blocked neurite growth promoting effects of CDDO as witnessed by the reduced neurite outgrowth and lengths (**Figures 4A,B**). Also, pretreatment with T0070907 significantly reduced the percentage of cells bearing more than two neurites compared to that of CDDO treated cells (**Figure 4C**). T0070907 inhibited CDDO induced neurite outgrowth at a various combination of concentrations (Supplementary Figure 2B). Pretreatment with T0070907 restored the CDDO induced loss in cell viability (**Figures 4D,E**). Although T0070907 inhibited CDDO induced morphological changes, the *TUBB3* mRNA levels were unaltered by antagonist pretreatment; however, the immunofluorescence analysis displayed reduced expression of β 3-tubulin compared to that of CDDO treated cells (**Figures 5A,C**, Supplementary Figures 8, 9). As shown in **Figures 5B,D**; clear down-regulation of the differentiation marker NSE was observed after pretreatment with an antagonist at both RNA and protein level. Collectively, T0070907 certainly inhibited neurite outgrowth, reduced the percentage of cells bearing more than





FIGURE 2 | Continued

two neurites, and decreased the expression of differentiation markers indicating that PPAR γ receptor signaling is implicated in reprogramming IMR32 cells to overcome differentiation block.

The antagonist was neither found to restore MYCN mRNA levels that were reduced by CDDO nor to have any contribution

in the regulation of PPARG mRNA levels (Figures 6A,D). However, it reversed CDDO regulated *NDRG1* and *ALK* mRNA expression to some extent (Figures 6B,C). Immunoblotting results indicate that active PPAR γ signaling was required to maintain *ALK* expression, as treatment with antagonist inhibited



its protein level. CDDO clearly did not regulate ALK protein expression while T0070907 caused a substantial decrease in it. T0070907 exerted a slight inhibition over CDDO induced

PPAR γ -2 protein level. T0070907 effectively reduced the CDDO induced NDRG1 expression, implying that PPAR γ signaling plays an important role in NDRG1 regulation. Moreover,




FIGURE 3 | Continued

FIGURE 3 | Continued

CDDO alone and in combination regulates expression of genes involved in IMR32 differentiation. RT-qPCR analysis was performed at day 3 and day 5 to quantify abundance of indicated mRNA transcripts (**A–D**) in IMR32 cells following treatment with CDDO 0.7 μ M and ATRA 10 μ M alone and in combination. The mRNA expressions were normalized to invariant control 18S. Error bars represent mean \pm SEM calculated using two-way ANOVA with Tukey's *post-hoc* test. (**E**) A representative immunoblot of indicated proteins of IMR32 cells treated with CDDO 0.7 μ M and ATRA 10 μ M alone and in combination for 5 days ($n = 2$). “-” denotes significance with respect to control cells (DMSO treated), “@” denotes significance with respect to CDDO 0.7 μ M and “#” denotes significance with respect to ATRA 10 μ M. DMSO (D); CDDO (C); CDDO + ATRA (CR); ATRA (R); four indicators: $p < 0.0001$; three indicators: $p \leq 0.001$; two indicators: $p \leq 0.01$; one indicator: $p \leq 0.05$.

treatment with antagonist alone had reduced NDRG1 expression (**Figure 6E**). Collectively, antagonist reversed CDDO induced signaling events in IMR32 cells with respect to ALK, NDRG1, and PPAR γ -2 protein level signifying that PPAR γ signaling is involved in regulating their levels.

Signaling Pathways Involved in CDDO and ATRA Induced IMR32 Differentiation

ERK1/2 and cAMP-response-element binding protein (CREB) activation was studied to identify the signaling mechanisms independent of receptor binding. CREB phosphorylation at Ser133 is considered important for the binding of its co-activator CREB binding protein (CBP) to form a transcriptionally active complex (Gonzalez and Montminy, 1989). Among the several identified kinases that activate CREB, we studied the phosphorylated ERK1/2 levels during IMR32 differentiation. CREB is not a direct downstream target of ERK1/2, instead it is phosphorylated by ERK1/2 activated 90 kDa Ribosomal Protein S6 Kinases (RSKs) (Xing et al., 1996). Treatment with ATRA 10 μ M for 72 h resulted in an increased ERK1/2 activation and phosphorylation of CREB. ATRA induced CREB activation was inhibited by co-treatment with CDDO 0.7 μ M. CDDO was found to decrease CREB phosphorylation without ERK1/2 activation. However, antagonizing PPAR γ signaling displayed increased levels of phosphorylated CREB without ERK1/2 activation. CDDO inhibited CREB activation, could perhaps be a PPAR γ dependent mechanism, as antagonist treatment resulted in an increased CREB phosphorylation (**Figure 7**). In summary, ATRA clearly activated ERK1/2-CREB signaling, whereas CDDO inhibited CREB activation via active PPAR γ signaling.

DISCUSSION

Achieving long term event free survival, overall survival, and decreasing disease reoccurrence for children with aggressive tumors who have undergone one of the various treatment options, have been clinically challenging. Neuroblastoma treatment regimens include observation, chemotherapy, surgery, radiation, and stem cell/bone marrow transplant depending on neuroblastoma stage. Consolidation therapies like differentiation therapy, antibody therapy, and immunotherapy are prescribed for treating minimal residual disease (Matthay et al., 1999; Yu et al., 2010; Lopci, 2015). Neuroblastoma tumors are often histopathologically diverse, displaying various degrees of cellular and extracellular maturation due to their neuroectodermal origin. Differentiation block is thus a characteristic of malignant neuroblastoma tumors, giving rise to tumor variants.

Naturally occurring retinoic acid isomers, ATRA and 9-cis retinoic acid (9-cis-RA) are key ligands for members of nuclear hormone superfamily which regulate retinoic acid mediated signaling (Heyman et al., 1992). The receptors (RXRs and RARs) mediate retinoid signal either by binding to specific DNA sequences like retinoic acid response elements (RAREs) as RAR-RXR heterodimers or RXR homodimers (Benkoussa et al., 2002; Idres et al., 2002). RXRs also heterodimerize with members of other nuclear hormone receptor family like PPAR, TH, VDR, LXRs, FXRs, PXR, CARs, and many other orphan receptors (Kliwer et al., 1992; Evans and Mangelsdorf, 2014). PPAR γ and RXR together bind as a complex specifically to PPAR response elements (PPREs) to regulate target gene expression. Besides this, the dimer can also interact with, and recruit coactivators to induce expression of specific genes (Forman et al., 1996; Ahmadian et al., 2013). Retinoid resistance is commonly observed *in vitro* as well as clinically, owing to the mutations in RAR gene or RAR receptor being truncated at C terminal end, and for many unknown reasons (Perrick et al., 1994). Since its discovery, CDDO is known to be a multifunctional molecule exhibiting several pharmacological activities. Previous findings have also indicated the role of PPAR γ stimulation in the differentiation of neuronal cell lines (Han S. et al., 2001; Jung et al., 2003; Chiang et al., 2014). CDDO has previously been through clinical trials for patients with relapsed and refractory leukemias; however, no responses were reported. CDDO also failed a tumor trial as it did not exhibit anti-tumor activity (Speranza et al., 2012).

In our study, we used IMR32 cell line which is a well-established *in vitro* model for experimenting differentiation using neurotrophic factors and synthetic compounds (Tumilowicz et al., 1970). IMR32 possesses most of the molecular signatures of aggressive neuroblastomas with unfavorable biological outcomes. Here, we report that simultaneous treatment with CDDO and ATRA induces neurite outgrowth, increases the percentage of cells bearing more than two neurites, reduces cell viability, up-regulates differentiation markers, and down-regulates *MYCN* mRNA level in IMR32 cells. We observed that maximum population of cells treated with CDDO especially in combination with ATRA underwent differentiation and eventually died. We noticed less reduction in viability with ATRA up to 5 days compared to the CDDO's individual and combination treatment. This was not unfamiliar as it is known that 9-cis-RA and 13-cis-RA are more potent anti-proliferative in nature (Han et al., 1995; Celay et al., 2013). Repeated treatments with CDDO after 5 days were found cytotoxic to cells, whereas, in combination with ATRA, gradual loss of cells bearing neurites and decrease




FIGURE 4 | Continued

FIGURE 4 | Continued


PPAR γ antagonist T0070907 inhibits CDDO induced neurite outgrowth and restores viability. Cells were pretreated with T0070907 5 μ M for 2 h followed by culture in presence of CDDO 0.7 μ M for 5 days and compared to cells treated with CDDO 0.7 μ M alone and control cells. **(A)** Cells were viewed under phase contrast microscope to study the morphological features of methylene blue stained IMR32 cells following treatment with CDDO 0.7 μ M. The images were captured on a microscope equipped with a monochrome camera. **(B)** Stained images in triplicates per treatment condition were opened in ImageJ software and were analyzed using Neuron growth plug-in. Neurites were semi-automatically traced and lengths were expressed as mean neurite lengths. Error bars represent mean \pm SEM calculated using one-way ANOVA and Tukey's multiple comparison test. **(C)** The number of cells in treated and non-treated conditions with more than two neurites were counted from random focuses and represented as a percentage. Error bars represent mean \pm SEM calculated using one-way ANOVA and Tukey's multiple comparison test. **(D)** Cell viability of IMR32 cells was analyzed using CellTiter-Glo luminescent cell viability assay. Cells were treated with indicated concentrations for 5 days. Data is represented as an average of two independent experiment performed in triplicates. Error bars represent mean \pm SEM calculated using one-way ANOVA and Tukey's multiple comparison test. **(E)** Cell viability of IMR32 cells was analyzed using trypan blue dye. Viable cells were counted manually using hemocytometer on day 2, 3, 4, and 5. Two independent experiments were performed in duplicates. Numbers on the y axis represent the total number of viable cells. Error bars represent mean \pm SEM calculated using two-way ANOVA and Tukey's multiple comparison test. "*" denotes significance with respect to control cells (DMSO treated), "@" denotes significance with respect to CDDO 0.7 μ M and "\$" denotes significance with respect to T0070907 5 μ M. DMSO (D); CDDO (C); T0070907 + CDDO (TC); T0070907 (T); four indicators: $p < 0.0001$; three indicators: $p \leq 0.001$; two indicators: $p \leq 0.01$; one indicator: $p \leq 0.05$.

in viability was observed. Treatment with ATRA at 15 μ M concentration for 5 days induced morphological differentiation as evidenced by neurite outgrowth without affecting growth in IMR32 cells (data not shown). The morphological changes between the groups were quite distinctive. Following CDDO and combination treatment, the extending neurites were found to make contacts with other neurites and cell bodies of neighboring cells, forming a branched neurite network. On the contrary, less neurite network was found in ATRA treated cells up to 5 days. Non-linear correlation between mRNA levels and protein abundance of differentiation markers (NSE and β 3-tubulin) may be due to differential post-transcriptional regulation exerted by CDDO and ATRA. Additionally, as observed in our study, the differentiation markers, although not regulated at transcriptional levels by ATRA, were regulated at translational levels, evidenced by immunofluorescence studies. Overexpression of Aryl Hydrocarbon Receptor (AHR) in SK-N-DZ cell line demonstrated neurite outgrowth without up-regulation of NSE mRNA levels (Wu et al., 2014). In another study, NSE mRNA up-regulation to 1.5-fold sufficiently displayed neurite formation in SHSY5Y cells treated with 10 μ M retinoic acid. Also the NSE mRNA level in IMR32 cells was found to be decreasing on day 5 (Maresca et al., 2012). In our study, in spite of distinct immunolabelling of β 3-tubulin observed in differentiated cells, its mRNA levels were not found to be regulated possibly due to a post-transcriptional auto-regulatory mechanism. Co-translational recognition of an emerging tetrapeptide (MREI) targets the ribosome bound tubulin mRNA for selective degradation. This process affects the cytoplasmic tubulin mRNAs and is dependent on the levels of un-polymerized tubulin subunit levels (Yen et al., 1988; Bachurski et al., 1994).

Because CDDO is a known partial PPAR γ agonist, to further investigate if the morphological changes and reduced viability required active PPAR γ signaling, we used T0070907, a selective PPAR γ antagonist (Lee et al., 2002). Pretreatment with T0070907 significantly reduced neurite lengths and increased viability in IMR32 cells implying that these effects of CDDO were dependent on PPAR γ receptor mediated signaling. Transcriptional activation of PPRE by CDDO has been shown in several cell lines using reporter assays (Lapillonne et al., 2003; Mix et al., 2004; Chintharlapalli et al., 2005). Similarly, synthetic PPAR γ agonists have been shown to inhibit cell growth

in several neuroblastoma cell lines (Valentiner et al., 2005). Our immunofluorescence analysis shows that T0070907 considerably decreased the expression of the differentiation markers β 3-tubulin and NSE, suggesting that active PPAR γ signaling was in part accountable for CDDO induced differentiation in IMR32 cells. The enhanced differentiation in IMR32 cells, by the combination of ATRA and CDDO, could perhaps be due to simultaneous activation of genes regulated under RAREs and PPREs; which mutually initiates a crosstalk between signaling pathways, influencing cell growth and differentiation. In the combination treatment, a decrease in cell viability accompanied the differentiation process, which was not observed in ATRA treated cells.


Restricted to embryonic development, MYCN proto-oncogene is a transcription factor belonging to basic helix loop helix zipper class, which governs assorted fundamental cellular processes. MYCN amplification is central to many advanced stage neuroblastomas which exhibit poor prognosis. MYCN shares the burden of being the cause of neuroblastoma by preventing differentiation and maintaining pluripotency at the expense of cells future (Cotterman and Knoepfler, 2009; Varlakhanova et al., 2010). MYCN along with other transcriptional cofactors regulates gene expression by heterodimerizing with Max and binding to E box sites mainly CATGTG; however, in the case of MYCN amplification, this binding becomes ambiguous (Murphy et al., 2009). In our study, we observed 80% reduction in MYCN mRNA level in CDDO treated cells whereas ATRA did not regulate MYCN mRNA level up to day 5. This would explain ATRA's inability to inhibit proliferation compared to CDDO as MYCN down-regulation is associated with and required for growth inhibitory responses of cells (Schweigerer et al., 1990; Negroni et al., 1991). MYCN down-regulation by CDDO resulted in re-expression of NDRG1 which is otherwise known to be repressed in neuroblastoma (Li and Kretzner, 2003). A study on NDRG1 expression in tumors obtained from neuroblastoma patients revealed its clinical significance with less expression being associated with tumor progression and poor survival (Matsushita et al., 2013). In our study, ATRA treated cells failed to up-regulate NDRG1. A simultaneous observation was that the differentiation induced by CDDO alone and in combination with ATRA was accompanied by accumulation of lipid droplets by day 5 (Supplementary Figure 11). This effect could supposedly



be an aftermath of *MYCN* reduction or other cellular events (Gulaya et al., 1989; Tanaka et al., 2012; Zirath et al., 2013; Muller et al., 2014).

Similar to *MYCN*, *ALK* amplification, and gain of function mutations are often correlated with poor outcome for

neuroblastomas. IMR32 cells contain wild type *ALK* and co-amplification of *MYCN* and *ALK* as fused single amplicon is also observed (Fransson et al., 2015). In a study performed by Passoni et al. using siRNA and small kinase inhibitor to inhibit active *ALK* in IMR32 cells, demonstrated that wild type *ALK* is







FIGURE 6 | Continued

FIGURE 6 | Continued

Effect of PPAR γ antagonist T0070907 on genes involved in IMR32 differentiation. RT-qPCR analysis was performed at day 3 and day 5 to quantify abundance of indicated mRNA transcripts (**A–D**) in IMR32 cells after pretreatment with T0070907 5 μ M for 2 h followed by treatment with CDDO 0.7 μ M and compared to cells treated with CDDO 0.7 μ M alone and control cells. The mRNA expressions were normalized to invariant control 18S. Error bars represent mean \pm SEM calculated using two-way ANOVA and Tukey's multiple comparison test. (**E**) A representative immunoblot of indicated proteins in IMR32 cells pretreated with T0070907 5 μ M for 2 h followed by treatment with CDDO 0.7 μ M for 5 days ($n = 2$). "*" denotes significance with respect to control cells (DMSO treated), "@" denotes significance with respect to CDDO 0.7 μ M and "\$" denotes significance with respect to T0070907 5 μ M. DMSO (D); CDDO (C); T0070907 + CDDO (TC); T0070907 (T); four indicators: $p < 0.0001$; three indicators: $p \leq 0.001$; two indicators: $p \leq 0.01$; one indicator: $p \leq 0.05$.



in part functionally responsible for the oncogenic property of IMR32 cells. Stimulation with the anti-ALK antibody, mAb46 showed a 40% increase of *MYCN* mRNA in IMR32 cells validating that active ALK contributes to *MYCN* level (Passoni et al., 2009). ATRA has been previously shown to down-regulate ALK in neuroblastoma cell lines and induce apoptosis selectively in those harboring activated ALK (NB-39-nu and SH-SY5Y) (Futami and Sakai, 2010). Our finding indicates that ATRA, but not CDDO, significantly decreases ALK expression.

Additionally, ATRA was found to increase PPAR γ level. CDDO did not up-regulate the basal level of PPAR γ in IMR32 cells, however previous findings in human SW-1353 chondrosarcoma cells report an increase in PPRE activity without change in mRNA and protein expression (Mix et al., 2004). Perhaps CDDO and ATRA together are able to regulate a certain subset of genes causing cells to differentiate and die eventually, a phenomenon not observed in ATRA treated cells up to 5 days. Moreover, CDDO as a partial PPAR γ agonist may recruit certain co-activators and release co-repressors regulating transcription of tissue specific genes involved in differentiation and cell survival. It has previously been shown using LAN5 cells that GW1929, a synthetic PPAR γ agonist can induce neurite outgrowth, cease proliferation and reduce *MYCN* expression. PPAR γ expression is also found to correlate with maturation stage of primary neuroblastoma tissue with differentiated phenotype having high nuclear PPAR γ expression

(Han S. W. et al., 2001). Contrarily, N2 media induced SHSY5Y differentiation and displayed cytoplasmic accumulation of PPAR γ . Moreover, silencing PPAR γ improved differentiation associated with up-regulation of other two PPAR isoforms (PPAR β/δ and PPAR α) (Di Giacomo et al., 2017). Besides, the phosphorylation status of PPAR γ also decides the responsiveness to PPAR γ agonists. Rosiglitazone induced PPRE activity in SK-N-AS but not in SH-SY5Y, probably due to presence of the phosphorylated PPAR γ in SHSY5Y cells (Cellai et al., 2006). Thus, the sensitivity of different neuroblastoma cell lines to different PPAR γ agonist varies owing to their cellular heterogeneity (Servidei et al., 2004). Furthermore, CDDO being electrophilic in nature can interact with several proteins affecting their function. Using affinity purification and mass spectroscopic approach, 577 binding partners were identified for a CDDO-Im, an imidazolidine derivative of CDDO (Yore et al., 2011).

CDDO and ATRA did not exhibit additive or synergistic activation of non-genomic mechanisms like ERK and CREB activation. Despite the combination being more effective in neurite outgrowth and growth inhibition, the downstream classic effectors like ERK and CREB were not found active. This suggests that CDDO and ATRA activated different signaling pathways, contributing to the biological effects observed. In IMR32 cells, we observed an increase in ERK and CREB phosphorylation in ATRA treated cells compared to control cells. Retinoic acid treatment in SK-N-SH and BE(2)-C cell lines

have been earlier reported to promote cell survival during the differentiation process, suggesting a potential mechanism for neuroblastoma resistance to retinoic acid therapy (Qiao et al., 2012). In our study, CREB activation in IMR32 cells by ATRA possibly leads to transcription of its target genes, initiating pro-survival signaling pathways (Bonni et al., 1995). In fact, CDDO considerably reduced ATRA induced ERK and CREB phosphorylation in the combination treatment, implying that cells die as/after they are differentiated. Thus, CDDO appears to induce differentiation and cell death in IMR32 cells via CREB and ERK independent mechanisms. However, antagonizing PPAR γ receptor caused increased CREB and decreased ERK activation in CDDO treated cells, suggesting that PPAR γ receptor signaling was responsible for the observed effects of CDDO. Therefore, CDDO being a synthetic and ATRA being a physiological molecule seem to trigger different molecular pathways leading to a common effect i.e., differentiation in IMR32 cells. Altogether, it appears that CDDO in combination with ATRA induces IMR32 differentiation via CREB independent and PPAR γ dependent signaling mechanisms.

Differentiation therapy aims to reprogram cells instead of directly killing them and thus it is received as a treatment option that is mild on young children. Our concern was to focus on evaluating CDDO from a perspective of differentiation therapy instead of chemotherapy, which is known to have various side effects. Because retinoic acid is in clinical practice, we attempted testing the effect of CDDO in combination with ATRA on neuroblastoma differentiation. In conclusion, our findings provide early evidence that combination treatment would be a more effective choice than a single drug treatment in differentiating and killing aggressive cells like IMR32.

Moreover, differentiated tumors are associated with favorable outcome. Additionally, many neuroblastomas are found refractive to retinoic acid therapy *in vivo* and therefore combination therapy holds a chance in the treatment of neuroblastoma. The results contribute to the current knowledge on neuroblastoma differentiation by showing that CDDO induced neurite outgrowth, decreased viability, up-regulation of differentiation markers and down-regulation of active CREB were PPAR γ dependent events in IMR32 cells. The highlight of this research in our opinion is that CDDO and ATRA together are capable of triggering events that help the IMR32 cells to differentiate and die. The *in vivo* efficacy of this combination in neuroblastoma xenograft models is yet to be studied.

AUTHOR CONTRIBUTIONS

PR conceptualized and designed the work. NC performed the experiments. PR and NC wrote the manuscript. PT and CL contributed in the discussion.

ACKNOWLEDGMENTS

The authors gratefully acknowledge VIT University, Vellore for the support through Seed Grant for Research.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <http://journal.frontiersin.org/article/10.3389/fnmol.2017.00310/full#supplementary-material>

REFERENCES

- Ahmadian, M., Suh, J. M., Hah, N., Liddle, C., Atkins, A. R., Downes, M., et al. (2013). PPAR γ signaling and metabolism: the good, the bad and the future. *Nat. Med.* 19, 557–566. doi: 10.1038/nm.3159
- Allan, J. M., and Travis, L. B. (2005). Mechanisms of therapy-related carcinogenesis. *Nat. Rev. Cancer* 5, 943–955. doi: 10.1038/nrc1749
- Andrew T., Glenn, P. Y. L., Marshall, M., and Tao, L. (2012). “Neuroblastoma: a malignancy due to cell differentiation block,” in *Neuroblastoma - Present and Future*, ed H. Shimada (Rijeka: InTech), 79–84.
- Bachurski, C. J., Theodorakis, N. G., Coulson, R. M., and Cleveland, D. W. (1994). An amino-terminal tetrapeptide specifies cotranslational degradation of beta-tubulin but not alpha-tubulin mRNAs. *Mol. Cell. Biol.* 14, 4076–4086. doi: 10.1128/MCB.14.6.4076
- Benkousa, M., Brand, C., Delmotte, M. H., Formstecher, P., and Lefebvre, P. (2002). Retinoic acid receptors inhibit AP1 activation by regulating extracellular signal-regulated kinase and CBP recruitment to an AP1-responsive promoter. *Mol. Cell. Biol.* 22, 4522–4534. doi: 10.1128/MCB.22.13.4522-4534.2002
- Bonni, A., Ginty, D. D., Dudek, H., and Greenberg, M. E. (1995). Serine 133-phosphorylated CREB induces transcription via a cooperative mechanism that may confer specificity to neurotrophin signals. *Mol. Cell. Neurosci.* 6, 168–183. doi: 10.1006/mcne.1995.1015
- Brodeur, G. M., and Bagatell, R. (2014). Mechanisms of neuroblastoma regression. *Nat. Rev. Clin. Oncol.* 11, 704–713. doi: 10.1038/nrclinonc.2014.168
- Celay, J., Blanco, I., Lazcoz, P., Rotinen, M., Castresana, J. S., and Encio, I. (2013). Changes in gene expression profiling of apoptotic genes in neuroblastoma cell lines upon retinoic acid treatment. *PLoS ONE* 8:e62771. doi: 10.1371/journal.pone.0062771
- Cellai, I., Benvenuti, S., Luciani, P., Galli, A., Ceni, E., Simi, L., et al. (2006). Antineoplastic effects of rosiglitazone and PPAR γ transactivation in neuroblastoma cells. *Br. J. Cancer* 95, 879–888. doi: 10.1038/sj.bjc.6603344
- Chiang, M. C., Cheng, Y. C., Chen, H. M., Liang, Y. J., and Yen, C. H. (2014). Rosiglitazone promotes neurite outgrowth and mitochondrial function in N2A cells via PPAR γ pathway. *Mitochondrion* 14, 7–17. doi: 10.1016/j.mito.2013.12.003
- Chintharlapalli, S., Papineni, S., Konopleva, M., Andreef, M., Samudio, I., and Safe, S. (2005). 2-Cyano-3,12-dioxoolean-1,9-dien-28-oic acid and related compounds inhibit growth of colon cancer cells through peroxisome proliferator-activated receptor gamma-dependent and -independent pathways. *Mol. Pharmacol.* 68, 119–128. doi: 10.1124/mol.105.011437
- Cotterman, R., and Knoepfler, P. S. (2009). N-Myc regulates expression of pluripotency genes in neuroblastoma including *lif*, *klf2*, *klf4*, and *lin28b*. *PLoS ONE* 4:e5799. doi: 10.1371/journal.pone.0005799
- Di Giacomo, E., Benedetti, E., Cristiano, L., Antonosante, A., d'Angelo, M., Fidoamore, A., et al. (2017). Roles of PPAR transcription factors in the energetic metabolic switch occurring during adult neurogenesis. *Cell Cycle* 16, 59–72. doi: 10.1080/15384101.2016.1252881
- Draberova, E., Lukas, Z., Ivanyi, D., Viklicky, V., and Draber, P. (1998). Expression of class III beta-tubulin in normal and neoplastic human tissues. *Histochem. Cell Biol.* 109, 231–239. doi: 10.1007/s004180050222
- El-Kenawi, A. E., and El-Remessy, A. B. (2013). Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales. *Br. J. Pharmacol.* 170, 712–729. doi: 10.1111/bph.12344

- Evans, R. M., and Mangelsdorf, D. J. (2014). Nuclear receptors, RXR, and the Big Bang. *Cell* 157, 255–266. doi: 10.1016/j.cell.2014.03.012
- Fanti, Z., De-Miguel, F. F., and Martinez-Perez, M. E. (2008). A method for semiautomatic tracing and morphological measuring of neurite outgrowth from DIC sequences. *Conf. Proc. IEEE Eng. Med. Biol. Soc.* 2008, 1196–1199. doi: 10.1109/IEMBS.2008.4649377
- Forman, B. M., Chen, J., and Evans, R. M. (1996). The peroxisome proliferator-activated receptors: ligands and activators. *Ann. N. Y. Acad. Sci.* 804, 266–275. doi: 10.1111/j.1749-6632.1996.tb18621.x
- Fransson, S., Hansson, M., Ruuth, K., Djos, A., Berbegall, A., Javanmardi, N., et al. (2015). Intragenic anaplastic lymphoma kinase (ALK) rearrangements: translocations as a novel mechanism of ALK activation in neuroblastoma tumors. *Genes Chromosomes Cancer* 54, 99–109. doi: 10.1002/gcc.22223
- Futami, H., and Sakai, R. (2010). All-trans retinoic acid downregulates ALK in neuroblastoma cell lines and induces apoptosis in neuroblastoma cell lines with activated ALK. *Cancer Lett.* 297, 220–225. doi: 10.1016/j.canlet.2010.05.014
- Gonzalez, G. A., and Montminy, M. R. (1989). Cyclic AMP stimulates somatostatin gene transcription by phosphorylation of CREB at serine 133. *Cell* 59, 675–680. doi: 10.1016/0092-8674(89)90013-5
- Gulaya, N. M., Volkov, G. L., Klimashevsky, V. M., Govseeva, N. N., and Melnik, A. A. (1989). Changes in lipid composition of neuroblastoma C1300 N18 cell during differentiation. *Neuroscience* 30, 153–164. doi: 10.1016/0306-4522(89)90361-8
- Han, G., Chang, B., Connor, M. J., and Sidell, N. (1995). Enhanced potency of 9-cis versus all-trans-retinoic acid to induce the differentiation of human neuroblastoma cells. *Differentiation* 59, 61–69. doi: 10.1046/j.1432-0436.1995.5910061.x
- Han, S. W., Greene, M. E., Pitts, J., Wada, R. K., and Sidell, N. (2001). Novel expression and function of peroxisome proliferator-activated receptor gamma (PPARgamma) in human neuroblastoma cells. *Clin. Cancer Res.* 7, 98–104.
- Han, S., Wada, R. K., and Sidell, N. (2001). Differentiation of human neuroblastoma by phenylacetate is mediated by peroxisome proliferator-activated receptor gamma. *Cancer Res.* 61, 3998–4002.
- Hannah, R., Beck, M., Moravec, R., and Riss, T. (2001). Cell Titer-Glo TN luminescent cell viability assay: a sensitive and rapid method for determining cell viability. *Cell Notes* 2, 11–13.
- Hasan, M. K., Nafady, A., Takatori, A., Kishida, S., Ohira, M., Suenaga, Y., et al. (2013). ALK is a MYCN target gene and regulates cell migration and invasion in neuroblastoma. *Sci. Rep.* 3:3450. doi: 10.1038/srep03450
- Heyman, R. A., Mangelsdorf, D. J., Dyck, J. A., Stein, R. B., Eichele, G., Evans, R. M., et al. (1992). 9-cis retinoic acid is a high affinity ligand for the retinoid X receptor. *Cell* 68, 397–406. doi: 10.1016/0092-8674(92)90479-V
- Honda, T., Gribble, G. W., Suh, N., Finlay, H. J., Rounds, B. V., Bore, L., et al. (2000). Novel synthetic oleanane and ursane triterpenoids with various enone functionalities in ring A as inhibitors of nitric oxide production in mouse macrophages. *J. Med. Chem.* 43, 1866–1877. doi: 10.1021/jm000008j
- Honda, T., Rounds, B. V., Bore, L., Favaloro, F. G. Jr., Gribble, G. W., Suh, N., et al. (1999). Novel synthetic oleanane triterpenoids: a series of highly active inhibitors of nitric oxide production in mouse macrophages. *Bioorg. Med. Chem. Lett.* 9, 3429–3434. doi: 10.1016/S0960-894X(99)00623-X
- Idres, N., Marill, J., Flexor, M. A., and Chabot, G. G. (2002). Activation of retinoic acid receptor-dependent transcription by all-trans-retinoic acid metabolites and isomers. *J. Biol. Chem.* 277, 31491–31498. doi: 10.1074/jbc.M205016200
- Ikeda, T., Nakata, Y., Kimura, F., Sato, K., Anderson, K., Motoyoshi, K., et al. (2004). Induction of redox imbalance and apoptosis in multiple myeloma cells by the novel triterpenoid 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid. *Mol. Cancer Ther.* 3, 39–45.
- Ito, Y., Pandey, P., Sporn, M. B., Datta, R., Kharbanda, S., and Kufe, D. (2001). The novel triterpenoid CDDO induces apoptosis and differentiation of human osteosarcoma cells by a caspase-8 dependent mechanism. *Mol. Pharmacol.* 59, 1094–1099.
- Jimenez, J. J., and Yunis, A. A. (1987). Tumor cell rejection through terminal cell differentiation. *Science* 238, 1278–1280. doi: 10.1126/science.3685979
- Jung, G. S., Lee, K. M., Park, J. K., Choi, S. K., and Jeon, W. B. (2013). Morphogenetic and neuronal characterization of human neuroblastoma multicellular spheroids cultured under undifferentiated and all-trans-retinoic acid-differentiated conditions. *BMB Rep.* 46, 276–281. doi: 10.5483/BMBRep.2013.46.5.196
- Jung, K. M., Park, K. S., Oh, J. H., Jung, S. Y., Yang, K. H., Song, Y. S., et al. (2003). Activation of p38 mitogen-activated protein kinase and activator protein-1 during the promotion of neurite extension of PC-12 cells by 15-deoxy-delta12,14-prostaglandin J2. *Mol. Pharmacol.* 63, 607–616. doi: 10.1124/mol.63.3.607
- Kawamata, H., Tachibana, M., Fujimori, T., and Imai, Y. (2006). Differentiation-inducing therapy for solid tumors. *Curr. Pharm. Des.* 12, 379–385. doi: 10.2174/138161206775201947
- Kliwer, S. A., Umesono, K., Noonan, D. J., Heyman, R. A., and Evans, R. M. (1992). Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. *Nature* 358, 771–774. doi: 10.1038/358771a0
- Kohl, N. E., Kanda, N., Schreck, R. R., Bruns, G., Latt, S. A., Gilbert, F., et al. (1983). Transposition and amplification of oncogene-related sequences in human neuroblastomas. *Cell* 35(2 Pt. 1), 359–367. doi: 10.1016/0092-8674(83)90169-1
- Koschmieder, S., D'Alo, F., Radomska, H., Schoneich, C., Chang, J. S., Konopleva, M., et al. (2007). CDDO induces granulocytic differentiation of myeloid leukemic blasts through translational up-regulation of p42 CCAAT enhancer binding protein alpha. *Blood* 110, 3695–3705. doi: 10.1182/blood-2006-11-058941
- Lapillonne, H., Konopleva, M., Tsao, T., Gold, D., McQueen, T., Sutherland, R. L., et al. (2003). Activation of peroxisome proliferator-activated receptor gamma by a novel synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest and apoptosis in breast cancer cells. *Cancer Res.* 63, 5926–5939.
- Lee, G., Elwood, F., McNally, J., Weiszmann, J., Lindstrom, M., Amaral, K., et al. (2002). T0070907, a selective ligand for peroxisome proliferator-activated receptor gamma, functions as an antagonist of biochemical and cellular activities. *J. Biol. Chem.* 277, 19649–19657. doi: 10.1074/jbc.M200743200
- Li, J., and Kretzner, L. (2003). The growth-inhibitory NdrG1 gene is a Myc negative target in human neuroblastomas and other cell types with overexpressed N- or c-myc. *Mol. Cell. Biochem.* 250, 91–105. doi: 10.1023/A:1024918328162
- Lopci, E. (2015). Neuroblastoma: from diagnosis to treatment. *J. Pediatr. Oncol.* 3, 38–42. doi: 10.14205/2309-3021.2015.03.02.2
- Lowry, O. H., Rosebrough, N. J., Farr, A. L., and Randall, R. J. (1951). Protein measurement with the Folin phenol reagent. *J. Biol. Chem.* 193, 265–275.
- Maresca, G., Natoli, M., Nardella, M., Arisi, I., Trisciuglio, D., Desideri, M., et al. (2012). LMNA knock-down affects differentiation and progression of human neuroblastoma cells. *PLoS ONE* 7:e45513. doi: 10.1371/journal.pone.0045513
- Matsushita, K., Uchida, K., Saigusa, S., Ide, S., Hashimoto, K., Koike, Y., et al. (2013). Low NDRG1 mRNA expression predicts a poor prognosis in neuroblastoma patients. *Pediatr. Surg. Int.* 29, 363–368. doi: 10.1007/s00383-012-3248-6
- Matthay, K. K., Villablanca, J. G., Seeger, R. C., Stram, D. O., Harris, R. E., Ramsay, N. K., et al. (1999). Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. *N Engl. J. Med.* 341, 1165–1173. doi: 10.1056/NEJM199910143411601
- Mix, K. S., Coon, C. I., Rosen, E. D., Suh, N., Sporn, M. B., and Brinckerhoff, C. E. (2004). Peroxisome proliferator-activated receptor-gamma-independent repression of collagenase gene expression by 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid and prostaglandin 15-deoxy-delta(12,14) J2: a role for Smad signaling. *Mol. Pharmacol.* 65, 309–318. doi: 10.1124/mol.65.2.309
- Mruk, D. D., and Cheng, C. Y. (2011). Enhanced chemiluminescence (ECL) for routine immunoblotting: an inexpensive alternative to commercially available kits. *Spermatogenesis* 1, 121–122. doi: 10.4161/spmg.1.2.16606
- Muller, I., Larsson, K., Frenzel, A., Oliynyk, G., Zirath, H., Prochownik, E. V., et al. (2014). Targeting of the MYCN protein with small molecule c-MYC inhibitors. *PLoS ONE* 9:e97285. doi: 10.1371/journal.pone.0097285
- Murphy, D. M., Buckley, P. G., Bryan, K., Das, S., Alcock, L., Foley, N. H., et al. (2009). Global MYCN transcription factor binding analysis in neuroblastoma reveals association with distinct E-box motifs and regions of DNA hypermethylation. *PLoS ONE* 4:e8154. doi: 10.1371/journal.pone.0008154
- Negrini, A., Scarpa, S., Romeo, A., Ferrari, S., Modesti, A., and Raschella, G. (1991). Decrease of proliferation rate and induction of differentiation by a

- MYCN antisense DNA oligomer in a human neuroblastoma cell line. *Cell Growth Differ.* 2, 511–518.
- Passoni, L., Longo, L., Collini, P., Coluccia, A. M., Bozzi, F., Podda, M., et al. (2009). Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients. *Cancer Res.* 69, 7338–7346. doi: 10.1158/0008-5472.CAN-08-4419
- Pemrick, S. M., Lucas, D. A., and Grippo, J. F. (1994). The retinoid receptors. *Leukemia* 8(Suppl. 3), S1–S10.
- Pierce, G. B., and Wallace, C. (1971). Differentiation of malignant to benign cells. *Cancer Res.* 31, 127–134.
- Qiao, J., Paul, P., Lee, S., Qiao, L., Josifi, E., Tiao, J. R., et al. (2012). PI3K/AKT and ERK regulate retinoic acid-induced neuroblastoma cellular differentiation. *Biochem. Biophys. Res. Commun.* 424, 421–426. doi: 10.1016/j.bbrc.2012.06.125
- Rothenberg, A. B., Berdon, W. E., D'Angio, G. J., Yamashiro, D. J., and Cowles, R. A. (2009). Neuroblastoma-remembering the three physicians who described it a century ago: James Homer Wright, William Pepper, and Robert Hutchison. *Pediatr. Radiol.* 39, 155–160. doi: 10.1007/s00247-008-1062-z
- Schleiermacher, G., Janoueix-Lerosey, I., and Delattre, O. (2014). Recent insights into the biology of neuroblastoma. *Int. J. Cancer* 135, 2249–2261. doi: 10.1002/ijc.29077
- Schmittgen, T. D., and Livak, K. J. (2008). Analyzing real-time PCR data by the comparative C(T) method. *Nat. Protoc.* 3, 1101–1108. doi: 10.1038/nprot.2008.73
- Schneider, C. A., Rasband, W. S., and Eliceiri, K. W. (2012). NIH Image to ImageJ: 25 years of image analysis. *Nat. Methods* 9, 671–675. doi: 10.1038/nmeth.2089
- Schwab, M., Alitalo, K., Klempnauer, K. H., Varmus, H. E., Bishop, J. M., Gilbert, F., et al. (1983). Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. *Nature* 305, 245–248. doi: 10.1038/305245a0
- Schweigerer, L., Breit, S., Wenzel, A., Tsunamoto, K., Ludwig, R., and Schwab, M. (1990). Augmented MYCN expression advances the malignant phenotype of human neuroblastoma cells: evidence for induction of autocrine growth factor activity. *Cancer Res.* 50, 4411–4416.
- Servidei, T., Morosetti, R., Ferlini, C., Cusano, G., Scambia, G., Mastrangelo, R., et al. (2004). The cellular response to PPAR γ ligands is related to the phenotype of neuroblastoma cell lines. *Oncol. Res.* 14, 345–354.
- Slack, J. M. W. (2012). *Essential Developmental Biology*. Wiley-Blackwell.
- Speranza, G., Gutierrez, M. E., Kummer, S., Strong, J. M., Parker, R. J., Collins, J., et al. (2012). Phase I study of the synthetic triterpenoid, 2-cyano-3, 12-dioxolean-1, 9-dien-28-oic acid (CDDO), in advanced solid tumors. *Cancer Chemother. Pharmacol.* 69, 431–438. doi: 10.1007/s00280-011-1712-y
- Tabe, Y., Konopleva, M., Kondo, Y., Contractor, R., Tsao, T., Konoplev, S., et al. (2007). PPAR γ -active triterpenoid CDDO enhances ATRA-induced differentiation in APL. *Cancer Biol. Ther.* 6, 1967–1977. doi: 10.4161/cbt.6.12.4982
- Tanaka, K., Tamiya-Koizumi, K., Hagiwara, K., Ito, H., Takagi, A., Kojima, T., et al. (2012). Role of down-regulated neutral ceramidase during all-trans retinoic acid-induced neuronal differentiation in SH-SY5Y neuroblastoma cells. *J. Biochem.* 151, 611–620. doi: 10.1093/jb/mvs033
- Tumilowicz, J. J., Nichols, W. W., Cholon, J. J., and Greene, A. E. (1970). Definition of a continuous human cell line derived from neuroblastoma. *Cancer Res.* 30, 2110–2118.
- Valentiner, U., Carlsson, M., Erttmann, R., Hildebrandt, H., and Schumacher, U. (2005). Ligands for the peroxisome proliferator-activated receptor- γ have inhibitory effects on growth of human neuroblastoma cells *in vitro*. *Toxicology* 213, 157–168. doi: 10.1016/j.tox.2005.05.024
- Varlakhanova, N. V., Cotterman, R. F., deVries, W. N., Morgan, J., Donahue, L. R., Murray, S., et al. (2010). myc maintains embryonic stem cell pluripotency and self-renewal. *Differentiation* 80, 9–19. doi: 10.1016/j.diff.2010.05.001
- Warrell, R. P., Frankel, S. R., Miller, W. H., Scheinberg, D. A., Itri, L. M., Hittelman, W. N., et al. (1991). Differentiation therapy of acute promyelocytic Leukemia with tretinoin (all-trans-retinoic Acid). *N. Engl. J. Med.* 324, 1385–1393. doi: 10.1056/NEJM199105163242002
- Wu, P. Y., Liao, Y. F., Juan, H. F., Huang, H. C., Wang, B. J., Lu, Y. L., et al. (2014). Aryl hydrocarbon receptor downregulates MYCN expression and promotes cell differentiation of neuroblastoma. *PLoS ONE* 9:e88795. doi: 10.1371/journal.pone.0088795
- Xing, J., Ginty, D. D., and Greenberg, M. E. (1996). Coupling of the RAS-MAPK pathway to gene activation by RSK2, a growth factor-regulated CREB kinase. *Science* 273, 959–963. doi: 10.1126/science.273.5277.959
- Yen, T. J., Machlin, P. S., and Cleveland, D. W. (1988). Autoregulated instability of beta-tubulin mRNAs by recognition of the nascent amino terminus of beta-tubulin. *Nature* 334, 580–585. doi: 10.1038/334580a0
- Yore, M. M., Kettenbach, A. N., Sporn, M. B., Gerber, S. A., and Liby, K. T. (2011). Proteomic analysis shows synthetic oleanane triterpenoid binds to mTOR. *PLoS ONE* 6:e22862. doi: 10.1371/journal.pone.0022862
- Yu, A. L., Gilman, A. L., Ozkaynak, M. F., London, W. B., Kreissman, S. G., Chen, H. X., et al. (2010). Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. *N. Engl. J. Med.* 363, 1324–1334. doi: 10.1056/NEJMoa0911123
- Zhang, C., Ni, X., Konopleva, M., Andreeff, M., and Duvic, M. (2004). The novel synthetic oleanane triterpenoid CDDO (2-cyano-3, 12-dioxolean-1, 9-dien-28-oic acid) induces apoptosis in Mycosis fungoides/Sézary syndrome cells. *J. Invest. Dermatol.* 123, 380–387. doi: 10.1111/j.0022-202X.2004.23207.x
- Zhou, J. (2014). Advances and prospects in cancer immunotherapy. *New J. Sci.* 2014, 13. doi: 10.1155/2014/745808
- Zirath, H., Frenzel, A., Olynyk, G., Segerstrom, L., Westermark, U. K., Larsson, K., et al. (2013). MYC inhibition induces metabolic changes leading to accumulation of lipid droplets in tumor cells. *Proc. Natl. Acad. Sci. U.S.A.* 110, 10258–10263. doi: 10.1073/pnas.1222404110

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2017 Chaudhari, Talwar, Lefebvre D'hellencourt and Ravanan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.